References
- Brooks BR. Amyotrophic Lateral Sclerosis Clinimetric Scales – Guidelines for Administration and Scoring. In: RM Herndon, ed. Handbook of Neurologic Rating Scales. New York: Demos Vermande, 1997: 31–79.
- Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987; 22: 328–333.
- Brooks BR. The Norris ALS Score. In: FC Rose, ed. ALS – From Charcot to the Present and into the Future. London: Smith-Gordon/Niigata: Nishimura 1994: 21–29.
- Guiloff RJ, Goonetilleke A. Natural history of amyotrophic lateral sclerosis – Observations with the Charing Cross Amyotrophic Lateral Sclerosis rating scales. In: GT Serratrice, TL Munsat, eds. Pathogenesis and Therapy of Amyotrophic Lateral Sclerosis. Philadelphia: Raven, 1995: 185–198.
- Meininger V, Bensimon G, Lacomblez L, Salachas F. Natural history of Amyotrophic Lateral Sclerosis: A Discussion. Chapter 23 in Serratrice Georges T, Munsat TL (Eds). Patho- genesis and therapy of Amyotrophic Lateral Sclerosis. Advances in Neurology volume 68. Lippincott-Raven, Philadelphia 1995; 199–207.
- Anonymous. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I–II Study Group. Arch Neurol 1996; 53: 141–147.
- Cedarbaum JM, Stambler N, Malta E. The ALSFRS-R: a revised ALS functional rating scale that incorporates assess- ments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999; 169: 13–21.
- Hillel AD, Miller RM, Yorkston K. Amyotrophic lateral scler- osis severity scale. Neuroepidemiology 1989; 8: 142–150.
- Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-toco- pherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS Riluzole-Tocopherol Study Group. ALS 2001; 2: 9–18.
- Dal Bello-Haas V, Kloos AD, Mitsumoto H. Physical therapy for a patient through six stages of amyotrophic lateral scler- osis. Phys Ther 1998; 78: 1312–1324.
- Rivière M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral scler- osis treated with riluzole. Arch Neurol 1998; 55: 526–528.
- Brooks BR, Shodis KA, Lewis DH. Natural history of amy- otrophic lateral sclerosis – Quantification of symptoms, signs, strength and function. In: GT Serratrice, TL Munsat, eds. Pathogenesis and Therapy of Amyotrophic Lateral Scler- osis. Philadelphia: Raven, 1995: 163–184.
- Jenkinson C, Fitzpatrick R, Brennan C, Bromberg M, Swash M. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: the ALSAQ-40. J Neurol 1999(Suppl 3); 246: III16–III21.
- Hobart JC, Thompson AJ. Assessment measures and clinical scales. In: RJ Guiloff, ed. Clinical Trials in Neurology. London: Springer Verlag, 2001: 17–28.
- Fayers PM, Hand DJ. Causal variables, indicator variables and measurement scales: an example from quality of life. J Roy Stat Soc A 2002; 165: 1–21.
- Cedarbaum JM, Stambler N. Performance of the Amyo- trophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials. J Neurol Sci 1997; 152(Suppl 1): S1–S9.
- Brooks BR, Sanjak M et al. Motor neurone disease: Basic designs, sample sizes and pitfalls. In: RJ Guiloff, ed. Clinical Trials in Neurology. London: Springer, 2001: 427–450.
- Brooks BR, Sanjak M et al. Delayed early loss of arm Com- puterized Isometric Muscle Strength (CIMS) in amyotrophic lateral sclerosis (ALS): A randomized placebo-controlled ancillary study to the phase 3 clinical trials of SR57746A- Xaliproden in patients treated and not treated with Riluzole (Abstract S24.003). Neurology 2001 (Suppl).
- Sinaki M, Mulder DW. Rehabilitation techniques for patients with amyotrophic lateral sclerosis. Mayo Clinic Proc 1978; 53: 173–178.
- Kurtzke JF. On the evaluation of disability in multiple scler- osis. Neurology 1998; 50: 317–326.
- Kurtzke JF. Natural history and clinical outcome measures for multiple sclerosis studies. Why at the present time does EDSS scale remain a preferred outcome measure to evaluate disease evolution? Neurol Sci 2000; 21: 339–341.